Anthony S Basile

Summary

Affiliation: DOV Pharmaceutical
Country: USA

Publications

  1. ncbi Anxioselective anxiolytics: can less be more?
    Anthony S Basile
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Eur J Pharmacol 500:441-51. 2004
  2. pmc Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
    Dmytro Berezhnoy
    Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA
    BMC Pharmacol 8:11. 2008
  3. ncbi Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain
    Anthony S Basile
    DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 321:1208-25. 2007
  4. ncbi Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
  5. ncbi The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity
    Joseph P Tizzano
    Department of Preclinical Pharmacology, DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 324:1111-26. 2008
  6. ncbi Triple reuptake inhibitors ("broad spectrum" antidepressants)
    Phil Skolnick
    DOV Pharmaceutical, Inc, USA
    CNS Neurol Disord Drug Targets 6:141-9. 2007
  7. ncbi Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration
    Heather C Salzberg-Brenhouse
    Division of Biological Research, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    J Pharmacol Exp Ther 306:218-28. 2003
  8. ncbi Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677
    Piotr Popik
    Behavioral Neuroscience Laboratory, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343, Krakow, Poland
    Cell Mol Neurobiol 26:857-73. 2006
  9. ncbi The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors
    Piotr Popik
    Behavioral Neuroscience, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    J Pharmacol Exp Ther 319:1244-52. 2006
  10. doi A murine model of retroviral encephalopathy
    Yoshitatsu Sei
    Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Protoc Neurosci . 2002

Collaborators

Detail Information

Publications17

  1. ncbi Anxioselective anxiolytics: can less be more?
    Anthony S Basile
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Eur J Pharmacol 500:441-51. 2004
    ..This article reviews the nonclinical and clinical studies of "anxioselective" anxiolytics that target GABA(A) receptors and discusses potential mechanisms subserving an anxioselective profile...
  2. pmc Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
    Dmytro Berezhnoy
    Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA
    BMC Pharmacol 8:11. 2008
    ....
  3. ncbi Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain
    Anthony S Basile
    DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 321:1208-25. 2007
    ....
  4. ncbi Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
    ..Clinical trials of extended release naltrexone for treating alcohol and opiate dependency are currently ongoing...
  5. ncbi The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity
    Joseph P Tizzano
    Department of Preclinical Pharmacology, DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 324:1111-26. 2008
    ..In summary, DOV 21947 is effective in causing a sustained and selective reduction in fat content and triglyceride levels in animal models of obesity without significantly altering vital organ function...
  6. ncbi Triple reuptake inhibitors ("broad spectrum" antidepressants)
    Phil Skolnick
    DOV Pharmaceutical, Inc, USA
    CNS Neurol Disord Drug Targets 6:141-9. 2007
    ..This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors...
  7. ncbi Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration
    Heather C Salzberg-Brenhouse
    Division of Biological Research, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    J Pharmacol Exp Ther 306:218-28. 2003
    ....
  8. ncbi Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677
    Piotr Popik
    Behavioral Neuroscience Laboratory, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343, Krakow, Poland
    Cell Mol Neurobiol 26:857-73. 2006
    ..5. In summary, DOV 102,677 is an orally active, "balanced" inhibitor of DAT, NET and SERT with therapeutic versatility in treating neuropsychiatric disorders beyond depression...
  9. ncbi The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors
    Piotr Popik
    Behavioral Neuroscience, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    J Pharmacol Exp Ther 319:1244-52. 2006
    ....
  10. doi A murine model of retroviral encephalopathy
    Yoshitatsu Sei
    Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Protoc Neurosci . 2002
    ..The model is robust, develops rapidly and does not require the use of human pathogens. In addition, the behavioral and neurochemical characteristics of this model is reviewed...
  11. ncbi Direct and indirect enhancement of GABAergic neurotransmission by ammonia: implications for the pathogenesis of hyperammonemic syndromes
    Anthony S Basile
    Laboratory of Bioorganic Chemistry, National Institutes of Health, Building 8, Room 121, MSC 0826, NIDDK, NIH, Bethesda, MD 20892, USA
    Neurochem Int 41:115-22. 2002
    ....
  12. pmc Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia
    Anthony S Basile
    Neuroscience Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:11452-7. 2002
    ..The finding that M5 receptor activity modulates both morphine reward and withdrawal processes suggests that M5 receptors may represent a novel target for the treatment of opiate addiction...
  13. ncbi M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity
    Thomas Seeger
    Department of Physiology, University of Munich, D 80336 Munich, Germany
    J Neurosci 24:10117-27. 2004
    ..Because impaired muscarinic cholinergic neurotransmission is associated with Alzheimer's disease and normal aging processes, these findings should be of considerable therapeutic relevance...
  14. ncbi Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice
    Weilie Zhang
    Laboratory of Bioorganic Chemistry, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892 0810, USA
    J Neurosci 22:6347-52. 2002
    ..These findings should contribute to a better understanding of the important functional roles that the muscarinic cholinergic system plays in striatal function...
  15. ncbi A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease
    Raymond T Bartus
    Alkermes Inc, Cambridge, MA, USA
    J Pharmacol Exp Ther 310:828-35. 2004
    ....
  16. ncbi Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology
    Masahisa Yamada
    Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bldg 8A, Room B1A 05, 8 Center Drive MSC 0810, Bethesda, MD 20892 0810, USA
    Life Sci 74:345-53. 2003
    ..These findings may lead to novel therapeutic strategies for the treatment of drug addiction and certain cerebrovascular disorders...
  17. ncbi Peripheral benzodiazepine receptors and mitochondrial function
    Pierre Casellas
    Department of Immunology Oncology, Sanofi Synthelabo, Montpellier, France
    Neurochem Int 40:475-86. 2002
    ....